Invitation to MorphoSys’ Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

On July 30, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) reported that it will publish its results for the second quarter and first half of 2020 on August 5, 2020 at 10:00pm CEST (9:00pm BST; 4:00pm EDT) (Press release, MorphoSys, JUL 30, 2020, View Source [SID1234562565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys’ Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.

Date of the conference call: Thursday, August 6, 2020
Time: 2:00pm CEST (1:00pm BST, 8:00am EDT)
Dial-in numbers:
Germany: +49 69 201 744 220
United Kingdom: +44 203 009 2470
USA: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 43014391#
Please dial in 10 minutes before the beginning of the conference.

A live webcast and slides will be made available at www.morphosys.com.

Approximately two hours after the call, a slide-synchronized audio replay of the conference and a transcript of the prepared remarks will be available on www.morphosys.com.

Kura Oncology to Report Second Quarter 2020 Financial Results

On July 30, 2020 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, reported that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020 (Press release, Kura Oncology, JUL 30, 2020, View Source [SID1234562581]). Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live call may be accessed by dialing (866) 278-7953 for domestic callers and (323) 347-3281 for international callers and entering the conference code: 1697775. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020

On July 30, 2020 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that the company will release its second quarter 2020 financial results after the market closes on Thursday, August 13, 2020 (Press release, CohBar, JUL 30, 2020, View Source [SID1234562598]). Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the Conference Call and Slide Presentation:

Date: August 13, 2020
Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference Audio

Dial-in U.S. and Canada: (877) 451-6152
Dial-in International: (201) 389-0879
Conference ID No.: 13707178
Slide Presentation

Go to www.webex.com, click on the ‘Join a Meeting’ button and enter meeting number 145 324 6260 and Password CWBR, or
Go to www.cohbar.com and click on Q2 2020 Shareholder Presentation at top of homepage.
For individuals participating in the Investor Call and Slide Presentation, please call into the conference audio and log into Webex approximately 10 minutes prior to its start.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on August 13, 2020, through 11:59 p.m. Eastern Time on September 3, 2020. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13707178. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period.

Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

On July 30, 2020 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that it will release its second quarter 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets (Press release, Syndax, JUL 30, 2020, View Source [SID1234562553]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, August 6, to discuss the Company’s financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website at www.syndax.com.
Alternatively, the conference call may be accessed through the following:

Conference ID: 8998873
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: View Source

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website, www.syndax.com.

Preclinical Toxicology Studies Support Planned Phase 1 Clinical Trial

On July 30, 2020 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported that it has received preliminary final results from the preclinical toxicology studies being conducted with its FAK inhibitor, AMP945 (Press release, Amplia Therapeutics, JUL 30, 2020, View Source;[email protected] [SID1234561580]). These data, together with those produced from the preclinical toxicology program to date, have not identified any toxicities that are likely to prevent a Phase 1 trial in healthy volunteers from progressing later this year as planned.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The toxicology studies were conducted under a Good Laboratory Practice (GLP) quality framework and included repeat-dose administration of AMP945 in two species. Data from the repeat-dose studies allows the identification of a No Observed Adverse Effect Level (NOAEL) which can be used to determine the starting dose for the planned Phase 1 clincial trial. The Company is expecting to receive the consolidated report from these studies in late July.

Subject to approval from an independent Human Research Ethics Committee (HREC) and adequate funding, Amplia is planning to conduct the Phase 1 trial under the Australian Clinical Trials Notification (CTN) scheme. The aims of the trial will be to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AMP945 when given as single and multiple doses.

The trial is expected to take 6-9 months from first patient enrolment to collection of final data, with completion expected by mid-2021. Data from the Phase 1 trial will support the progression of AMP945 into a Phase 2 clinical trial program in patients with various solid cancers and/or with fibrotic diseases, such as idiopathic lung fibrosis (IPF), expected to commence in late 2021.

Dr John Lambert, Amplia’s CEO and Managing Director commented "we are very pleased to receive the final piece of key data from the preclinical studies conducted to date. Achieving this milestone marks an important transition for Amplia as we transform the Company into a clinical-stage drug development company."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics